Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Biofrontera reports Q1 2021 financial results
Biofrontera AGMay 11, 2021 GMT
Leverkusen, Germany, May 11, 2021 (GLOBE NEWSWIRE) Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021.
Q1 2021 key financial figures and business performance
In EUR thousands
ADVERTISEMENT
Biofrontera’s business performance was encouragingly positive after an initial, pandemic-related slow start at the beginning of the year. As expected, business activities and consequently sales continue to be heavily dependent on the development of the pandemic and the related easing of lockdown measures in our sales markets. While sales in the first quarter were 15% lower overall than in the same period of the previous year, the sales development since March shows
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Biofrontera reports preliminary revenue for the month of April 2021
Biofrontera AGMay 6, 2021 GMT
Leverkusen, Germany, May 06, 2021 (GLOBE NEWSWIRE) Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of April 2021.
The Company’s preliminary, unaudited revenue from product sales in April 2021 amounted to approximately EUR 2,491 thousand, compared to EUR 492 thousand in April 2020, an increase of 406%. Total revenue for the month of April 2020 was EUR 6,602 thousand, whereby April 2020 included a one-time down payment of EUR 6,000 thousand from Maruho Co., Ltd as part of a license and supply agreement.
Nachricht vom 06.05.2021 | 07:00
SHOP APOTHEKE EUROPE: Strong Start into 2021 with 22.4% Sales Growth and 2.0% adj. EBITDA Margin.
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Quarterly / Interim Statement/Quarter Results
06.05.2021 / 07:00
NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.
SHOP APOTHEKE EUROPE: Strong Start into 2021 with 22.4% Sales Growth and 2.0% adj. EBITDA Margin.
Group sales up 22.4% in Q1 to EUR 284 million.
DACH segment +15%, International segment +71%.
Earnings on track: adj. EBITDA margin 2.0%.
Record year-over-year customer growth of 1.8 to 6.8 million; up half a million in Q1.
Digital medication management expanded by the acquisitions of SMARTPATIENT and MEDAPP, the latter also enabling the entrance into the Dutch Rx market.
Preliminary results for Q1-2021 significantly improved
DGAP-Ad-hoc: H&R GmbH & Co. KGaA / Key word(s): Preliminary Results/Quarter Results
H&R GmbH & Co. KGaA: Preliminary results for Q1-2021 significantly improved
27-Apr-2021 / 12:50 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Insider information pursuant to Article 17 of the Market Abuse Regulation [MAR]
Preliminary business results for the 1
st quarter 2021
st quarter 2021 published
Sales of EUR 241.4 million below the same quarter of the previous year